Quantcast

Latest Lymphocytic Leukemia Stories

2014-12-06 16:21:17

- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.

2014-12-06 16:21:12

--CHOP-Led Pilot Study Engineers Patients' Own Immune Cells to Hunt Down Cancer Cells in Blood-- PHILADELPHIA, Dec.

2014-12-06 16:21:05

- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1] EAST HANOVER, N.J., Dec.

2014-12-06 12:21:46

78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.

2014-12-05 08:25:08

U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, Calif., Dec. 5, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-12-02 12:31:08

Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.

2014-12-01 04:22:06

Filing completed less than two months after first European approval for IMBRUVICA® SUNNYVALE, Calif., Dec. 1, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-11-26 12:26:43

Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)


Word of the Day
chauffeuse
  • A woman chauffeur.
  • A woman who operates an automobile.
The word 'chaffeuse' comes from French, and is the feminine form of 'chauffeur'.
Related